NASDAQ:JANX | Free Cash Flow | Janux Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$12.34M$273,000.00-$12.61M
2025-12-31-$28.54M$106,000.00-$28.65M
2025-03-31-$17.02M$371,000.00-$17.4M
2024-12-31-$16.73M$42,000.00-$16.77M
2024-03-31-$14.84M$197,000.00-$15.03M
2023-12-31-$9.9M$515,000.00-$10.42M
2023-03-31-$13.91M$285,000.00-$14.2M
2022-12-31-$11.91M$2.06M-$13.97M
2022-03-31-$11.52M$971,000.00-$12.49M
2021-12-31-$10.48M$1.17M-$11.65M
2021-03-31$5.56M$153,000.00$5.41M
2020-12-31-$1.63M$0.00-$1.63M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$82.24M$1.04M-$83.28M
2024-12-31-$43.81M$359,000.00-$44.17M
2023-12-31-$50.58M$1.85M-$52.43M
2022-12-31-$42.92M$6.45M-$49.37M
2021-12-31-$16.98M$1.48M-$18.46M
2020-12-31-$4.37M$0.00-$4.37M